SCHEMBL18281149

SCHEMBL18281149

Cc1ccc2c(c1)c(C(=O)O)cc1ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
RXFP1 Q9HBX9 1/20 0.58
ALDH1A1 P00352 5/20 0.54
KDM4E B2RXH2 3/20 0.54
HSD17B10 Q99714 2/20 0.54
GPR35 Q9HC97 2/20 0.47
POLB P06746 1/20 0.47
SOS1 Q07889 1/20 0.47
HPGD P15428 3/20 0.46
NR4A1 P22736 1/20 0.46
NR4A2 P43354 1/20 0.46
NR4A3 Q92570 1/20 0.46
CYP1A2 P05177 1/20 0.46
GLA P06280 1/20 0.46
CYP2C19 P33261 1/20 0.46
CYP2D6 P10635 1/20 0.45
MPL P40238 1/20 0.45
CSNK2A1 P68400 1/20 0.44
MYC P01106 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18281167 0.88 MEN1 (0.53) MEN1KMT2ARXFP1ALDH1A1KDM4E
SCHEMBL522958 0.84 MEN1 (0.71) MEN1KMT2ARXFP1ALDH1A1KDM4E
SCHEMBL9476237 0.80 RXFP1 (0.57) MEN1KMT2ARXFP1ALDH1A1KDM4E
SCHEMBL3391887 0.79 NR4A1 (0.57) MEN1KMT2ARXFP1ALDH1A1KDM4E
SCHEMBL31256575 0.79 NR4A1 (0.57) MEN1KMT2ARXFP1ALDH1A1KDM4E
SCHEMBL6349823 0.78 POLB (0.54) MEN1KMT2ARXFP1ALDH1A1KDM4E
SCHEMBL31522164 0.77 PTPN1 (0.66) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL344157 0.77 PTPN1 (0.66) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL5833643 0.76 CSNK2A1 (0.55) MEN1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL6917252 0.76 PTPN1 (0.64) MEN1KMT2AALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11029303-B2 PAH antibodies and uses thereof THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2021-06-08 US disclosed
WO-2016196638-A2 PAH ANTIBODIES AND USES THEREOF THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11029303-B2 PAH antibodies and uses thereof PAH, AHR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MEN1 1080/4885KMT2A 726/4885RXFP1 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.